EU Legislative Reform
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
On 26 April 2023, the European Commission adopted a proposal for a new Directive and a new Regulation, which will revise and replace the existing general pharmaceutical legislation and represent the largest reform for the rules governing medicines in the EU in almost 20 years. The next step involves the legislation reform package entering the legislative process at the European Parliament and the Council of the EU for debate and potential amendments. The final version of the package will need to be approved by the EU member states by a qualified majority vote.

EU Orphan Drug Law Reform Will See Innovation Drop By 12%, Industry Warns
The European Commission’s proposals to overhaul the EU pharma legislation, which will see some orphan drug incentives cut, would cause a “significant dip in innovation,” according to number crunching from pharma industry association EFPIA.

Dissent In Parliament As Commission Claims EU Pharma Revision Will Improve Competitiveness and Access
Proposals on regulatory data protection and transferable exclusivity vouchers to encourage antimicrobial R&D have received mixed reactions from the parliament’s rapporteurs for the draft legislation.

Lawmakers Finally Kick Off Debate On EU Pharma Overhaul
The late delivery of the “pharmaceutical package” leaves little time for the legislative process to take shape before European Parliament elections are held in June next year.

EU Pharmaceutical Reform: A Delicate Negotiation
The European Commission may well be flexible over its proposals on data protection periods, but it is unlikely to give ground on plans to restructure the European Medicines Agency and to introduce a new temporary emergency marketing authorization, says lawyer Vincenzo Salvatore.

Will Shorter EU Regulatory Timelines Mean Unfeasible Joint Clinical Assessment Timelines?
Faster regulatory reviews proposed in the European Commission’s pharmaceutical reform package could impact the EU-level joint clinical assessments that go live from 2025.

EU Country Coalition Wants New Unmet Needs System To Incentivize The Right Innovation
The European Commission’s proposals for legislative reform in the pharmaceutical sector are welcome but must go further to address patient and societal needs, says a coalition of five EU countries dedicated to improving access to medicines.

EU Pharma Revision Proposals Still Awaiting Start Of Legislative Debate
The texts of the proposals cannot be formally presented to the European Parliament until they have been translated into all of the EU’s official languages.

EC Says ‘Bolar Exemption’ Should Cover Pricing, Reimbursement & HTA Processes
Pricing and reimbursement processes as well as health technology assessments should be explicitly included in the procedures that can be conducted for generic and biosimilar products without infringing patent rights, according to the European Commission’s legislative revision proposals.

German HTA Body Calls For EU Legislative Reforms To Foster Better R&D Environment
Proposed revisions to the EU pharmaceutical legislation should do more to deliver a better data and research infrastructure to help propel European drug development and better clinical research, says IQWiG, Germany’s health technology assessment institute.

German HTA Body: EU Legislative Reforms Must Do More To Incentivize Use Of Comparative Data
IQWiG, Germany’s health technology assessment (HTA) body, is calling for EU legislative reforms to do more to promote better evidence that addresses the questions health systems and HTAs have about the added benefits of new medicines.

Pharma Revision Will Hasten EU’s R&D Decline, Says EFPIA’s New Presidency Team
The European pharma industry group fears planned cuts in regulatory data protection and orphan drug exclusivity periods will hit innovation but says it is ready to work with legislators to close what it sees as an R&D gap between the EU on the one hand and the US and Asia on the other.

EU Regulatory Reforms Mean Many Orphan Drug Producers Won’t Benefit From Incentives
The EU’s regulatory reform package if unchanged could make orphan drug development less attractive, warn industry representatives.

What Would An EU ‘Regulatory Sandbox’ Bring To New Drug Development?
Digital health, AI, real-world evidence and “proactive learning” are key components of the EU’s proposals for new ways of regulating novel medicines, but only time will tell which products might benefit from the flexibilities offered by the “regulatory sandbox.”

EU Pharma Revision: Legislators Prepare For Long-Haul Debate
The European Parliament and the Council of the EU are preparing their positions on the planned overhaul of the EU medicines legislation ahead of discussions that are expected to take two to three years.

EU Drug Approvals Could Be Denied If Environmental Risks Not Properly Assessed
As part of its revision of the EU medicines legislation, the European Commission is proposing tighter rules to reduce the environmental impact of medicines. Companies may want to start thinking now about whether their current environmental risk assessment processes would meet the likely new requirements.

EU Pharma Revision Of Hospital Exemptions For ATMPs 'Is Unsatisfactory'
The EU legislative overhaul falls short on dealing with the issue of hospital exemptions for advanced therapies, says the Alliance For Regenerative Medicine.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.